EHA 2019 – presentationer och artiklar

Under 2019 European Hematology Association (EHA) kongressen presenterade Oncopeptides uppdaterade interimsdata från den pågående fas 1/2-studien ANCHOR, data från fas 1/2-studien O-12-M1 samt uppdaterade effekt- och säkerhetsdata från den pågående pivotala fas 2-studien HORIZON. Dessa presentationer samt publikationer i media presenteras nedan. Posterpresentationer av ANCHOR och O-12-M1, muntlig presentation av HORIZON av professor Paul G. Richardson samt fler externa länkar och video gällande publikationer i media.

Intervju med professor Paul G. Richardson

Artikel i Multiple Myeloma Hub

EHA 2019 | Updated analysis of the HORIZON phase II study: Melflufen + dexamethasone for RRMM. Se artikeln som bifogad fil under dokument.

Artikel i MedCity News (BioPharma) – av Alaric DeArment:

Oncopeptides looks forward to updates on myeloma drug at European hematology conference
In a phone interview, CEO Jakob Lindberg indicated that data so far showed a study was doing well in terms of progression-free survival.
Se länk nedan.

Artikel i M2 Pharma:

Oncopeptides to present new data from phase 1/2 ANCHOR trail at 24th EHA Congress
Oncopeptides AB (STO:ONCO) on Friday announced the presentation of new data at the 24th Congress of the European Haematology Association (EHA) in Amsterdam, including updated interim data from the ongoing phase 1/2 ANCHOR study and data from its phase 1/2 O-12-M1 study.

The company said that interim data from its ongoing, pivotal phase 2 HORIZON study will also be presented on 16 June 2019 as an oral presentation by Professor Paul G. Richardson, Professor of Medicine at Harvard Medical School and clinical programme leader, director of Clinical Research at the Jerome Lipper Multiple Myeloma Centre Dana-Farber Cancer Institute in Boston, Massachusetts, US.

The full posters presented at EHA can be found on the company webpage at Investors & media / Presentations / 2019 EHA.
According to the company, the results from the O-12-M1 study demonstrate that melflufen can offer disease stabilisation and favourable time to the next treatment. It is strategically important from a health economic perspective and supports the potential that melflufen may play an important role in the treatment of patients with RRMM.

ANCHOR is a phase 1/2 study where melflufen and dexamethasone is dosed in combination with either bortezomib or daratumumab. All patients must have 1-4 prior lines of therapy and be refractory (or intolerant) to an immunomodulary agent (IMiD) or a proteasome inhibitor (PI) or both. This study is currently open for enrolment at multiple sites globally.
Oncopeptides is a pharmaceutical company focused on the development of targeted therapies for difficult-to-treat haematological cancers.